Theresa Grover
Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 19 | 2026 | 188 | 4.090 |
Why?
| | Intensive Care Units, Neonatal | 37 | 2026 | 295 | 4.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 10 | 2026 | 370 | 1.850 |
Why?
| | Infant, Newborn | 63 | 2026 | 6460 | 1.620 |
Why?
| | Infant, Premature | 15 | 2026 | 622 | 1.540 |
Why?
| | Catheterization, Central Venous | 6 | 2025 | 121 | 1.330 |
Why?
| | Cross Infection | 3 | 2025 | 258 | 1.280 |
Why?
| | Bacterial Infections | 2 | 2025 | 247 | 1.220 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2024 | 427 | 1.050 |
Why?
| | Central Venous Catheters | 5 | 2025 | 53 | 1.010 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 209 | 1.000 |
Why?
| | Gestational Age | 18 | 2026 | 990 | 0.930 |
Why?
| | Pulmonary Circulation | 15 | 2011 | 431 | 0.890 |
Why?
| | Length of Stay | 12 | 2026 | 1358 | 0.860 |
Why?
| | Enteral Nutrition | 4 | 2025 | 212 | 0.840 |
Why?
| | Mycoses | 1 | 2025 | 87 | 0.840 |
Why?
| | Catheter-Related Infections | 4 | 2017 | 101 | 0.740 |
Why?
| | Gastroschisis | 4 | 2025 | 32 | 0.690 |
Why?
| | Infant, Premature, Diseases | 3 | 2026 | 113 | 0.640 |
Why?
| | Hypertension, Pulmonary | 11 | 2021 | 1957 | 0.590 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 116 | 0.590 |
Why?
| | Bottle Feeding | 1 | 2019 | 19 | 0.580 |
Why?
| | Retrospective Studies | 35 | 2026 | 17438 | 0.580 |
Why?
| | Quality Improvement | 9 | 2024 | 1354 | 0.580 |
Why?
| | Infant | 28 | 2026 | 10114 | 0.580 |
Why?
| | Fetus | 14 | 2020 | 800 | 0.570 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.550 |
Why?
| | Hospitals, Pediatric | 6 | 2025 | 561 | 0.550 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2007 | 545 | 0.540 |
Why?
| | Bacteremia | 4 | 2024 | 218 | 0.530 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1591 | 0.520 |
Why?
| | Lung | 10 | 2011 | 4122 | 0.510 |
Why?
| | Parenteral Nutrition, Total | 1 | 2017 | 27 | 0.500 |
Why?
| | Postoperative Complications | 5 | 2025 | 3034 | 0.500 |
Why?
| | Patient Discharge | 7 | 2026 | 997 | 0.480 |
Why?
| | Vasodilation | 11 | 2011 | 519 | 0.480 |
Why?
| | Weight Gain | 2 | 2017 | 562 | 0.470 |
Why?
| | Sheep | 20 | 2011 | 870 | 0.470 |
Why?
| | Infant Mortality | 3 | 2026 | 127 | 0.460 |
Why?
| | Intensive Care, Neonatal | 4 | 2020 | 41 | 0.440 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 44 | 0.440 |
Why?
| | Developmental Disabilities | 1 | 2018 | 281 | 0.430 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 64 | 0.420 |
Why?
| | Patient Education as Topic | 1 | 2019 | 770 | 0.400 |
Why?
| | Nitric Oxide Synthase | 9 | 2006 | 233 | 0.390 |
Why?
| | Tracheostomy | 3 | 2024 | 136 | 0.390 |
Why?
| | Humans | 66 | 2026 | 146342 | 0.380 |
Why?
| | Female | 56 | 2026 | 79499 | 0.380 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 61 | 0.370 |
Why?
| | Lymphokines | 2 | 2002 | 127 | 0.370 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1942 | 0.360 |
Why?
| | Heart Defects, Congenital | 3 | 2026 | 923 | 0.350 |
Why?
| | Hospitalization | 3 | 2021 | 2475 | 0.350 |
Why?
| | Nitric Oxide | 10 | 2011 | 883 | 0.350 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2002 | 372 | 0.330 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 307 | 0.330 |
Why?
| | Hospital Mortality | 5 | 2026 | 1051 | 0.330 |
Why?
| | Social Determinants of Health | 2 | 2026 | 317 | 0.330 |
Why?
| | Pulmonary Artery | 11 | 2011 | 1116 | 0.320 |
Why?
| | Male | 35 | 2026 | 73396 | 0.310 |
Why?
| | Parents | 1 | 2019 | 1394 | 0.310 |
Why?
| | Intubation, Intratracheal | 2 | 2024 | 330 | 0.300 |
Why?
| | Respiration, Artificial | 6 | 2026 | 711 | 0.300 |
Why?
| | Databases, Factual | 7 | 2025 | 1493 | 0.290 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2011 | 132 | 0.290 |
Why?
| | Anesthesia | 2 | 2023 | 257 | 0.280 |
Why?
| | Pregnancy | 23 | 2021 | 7230 | 0.270 |
Why?
| | Survival Rate | 4 | 2018 | 2092 | 0.270 |
Why?
| | Patient Care Bundles | 2 | 2019 | 30 | 0.260 |
Why?
| | Lung Diseases | 1 | 2014 | 787 | 0.260 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2007 | 199 | 0.240 |
Why?
| | Guideline Adherence | 4 | 2025 | 594 | 0.240 |
Why?
| | Fibrin | 1 | 2007 | 84 | 0.240 |
Why?
| | Fetal Diseases | 3 | 2004 | 192 | 0.240 |
Why?
| | Intestinal Atresia | 1 | 2025 | 16 | 0.230 |
Why?
| | Hernia, Diaphragmatic | 1 | 2026 | 64 | 0.230 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2026 | 26 | 0.230 |
Why?
| | Jejunum | 1 | 2025 | 36 | 0.230 |
Why?
| | Hospitals, High-Volume | 1 | 2026 | 51 | 0.230 |
Why?
| | Guanylate Cyclase | 4 | 2011 | 36 | 0.230 |
Why?
| | Multivariate Analysis | 5 | 2025 | 1543 | 0.230 |
Why?
| | Logistic Models | 6 | 2025 | 2126 | 0.220 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 385 | 0.220 |
Why?
| | Infection Control | 2 | 2017 | 174 | 0.220 |
Why?
| | Ileum | 1 | 2025 | 112 | 0.210 |
Why?
| | Bradycardia | 2 | 2024 | 63 | 0.210 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 299 | 0.210 |
Why?
| | Consensus | 2 | 2024 | 467 | 0.210 |
Why?
| | Ventilator Weaning | 1 | 2024 | 38 | 0.210 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2025 | 49 | 0.210 |
Why?
| | Anastomotic Leak | 1 | 2024 | 46 | 0.210 |
Why?
| | North America | 1 | 2025 | 300 | 0.210 |
Why?
| | Esophageal Atresia | 1 | 2024 | 32 | 0.210 |
Why?
| | Device Removal | 1 | 2025 | 149 | 0.210 |
Why?
| | Tracheoesophageal Fistula | 1 | 2024 | 38 | 0.200 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2024 | 22 | 0.200 |
Why?
| | Critical Pathways | 1 | 2025 | 104 | 0.200 |
Why?
| | Blood Culture | 1 | 2024 | 27 | 0.200 |
Why?
| | Cyclic GMP | 4 | 2011 | 88 | 0.200 |
Why?
| | Clinical Protocols | 1 | 2025 | 282 | 0.200 |
Why?
| | Severity of Illness Index | 6 | 2026 | 2921 | 0.190 |
Why?
| | Ductus Arteriosus | 6 | 2008 | 71 | 0.190 |
Why?
| | Laryngoscopy | 1 | 2024 | 122 | 0.190 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 287 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 350 | 0.180 |
Why?
| | Hemangioendothelioma | 1 | 2002 | 13 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.170 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 118 | 0.170 |
Why?
| | Time Factors | 7 | 2024 | 7109 | 0.170 |
Why?
| | Uterus | 1 | 2002 | 227 | 0.170 |
Why?
| | Patient Handoff | 1 | 2021 | 45 | 0.170 |
Why?
| | Retrognathia | 1 | 2020 | 4 | 0.160 |
Why?
| | Hepatitis B Vaccines | 1 | 2021 | 43 | 0.160 |
Why?
| | Animals, Newborn | 7 | 2009 | 888 | 0.160 |
Why?
| | Micrognathism | 1 | 2020 | 19 | 0.160 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 53 | 0.160 |
Why?
| | Hepatitis B | 1 | 2021 | 66 | 0.160 |
Why?
| | Betamethasone | 1 | 2000 | 21 | 0.160 |
Why?
| | Benzoates | 2 | 2011 | 48 | 0.160 |
Why?
| | Analgesia | 1 | 2021 | 106 | 0.160 |
Why?
| | Vascular Resistance | 6 | 2011 | 365 | 0.150 |
Why?
| | Ventricular Septum | 1 | 2019 | 8 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.150 |
Why?
| | Hypothermia | 1 | 2020 | 53 | 0.150 |
Why?
| | Incidence | 2 | 2018 | 2936 | 0.150 |
Why?
| | United States | 7 | 2025 | 16136 | 0.140 |
Why?
| | Cooperative Behavior | 3 | 2017 | 471 | 0.140 |
Why?
| | Food, Fortified | 1 | 2019 | 43 | 0.140 |
Why?
| | Airway Obstruction | 1 | 2020 | 152 | 0.140 |
Why?
| | Geographic Mapping | 1 | 2019 | 26 | 0.140 |
Why?
| | Blood Pressure | 5 | 2019 | 1765 | 0.140 |
Why?
| | Neonatology | 1 | 2019 | 36 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 213 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 952 | 0.140 |
Why?
| | Recombinant Proteins | 4 | 2005 | 1361 | 0.140 |
Why?
| | Animals | 22 | 2011 | 38107 | 0.130 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 179 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 330 | 0.130 |
Why?
| | Housing | 1 | 2019 | 142 | 0.130 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 117 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 235 | 0.130 |
Why?
| | Odds Ratio | 2 | 2020 | 1077 | 0.130 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 334 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 74 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 298 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 411 | 0.120 |
Why?
| | Premature Birth | 1 | 2020 | 390 | 0.120 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 67 | 0.120 |
Why?
| | Echocardiography | 1 | 2019 | 645 | 0.120 |
Why?
| | Disease Models, Animal | 6 | 2011 | 4580 | 0.120 |
Why?
| | Patient Readmission | 2 | 2019 | 778 | 0.120 |
Why?
| | Hemodynamics | 6 | 2011 | 1114 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 224 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2000 | 536 | 0.120 |
Why?
| | Child | 8 | 2023 | 22693 | 0.120 |
Why?
| | Risk Factors | 6 | 2026 | 10921 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 136 | 0.110 |
Why?
| | Risk Adjustment | 1 | 2016 | 86 | 0.110 |
Why?
| | Vasoconstriction | 2 | 2008 | 216 | 0.110 |
Why?
| | Clinical Nursing Research | 1 | 2015 | 11 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2002 | 776 | 0.110 |
Why?
| | Ligation | 3 | 2025 | 88 | 0.110 |
Why?
| | Communication | 1 | 2021 | 980 | 0.110 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2011 | 26 | 0.110 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2024 | 39 | 0.100 |
Why?
| | Enzyme Activation | 3 | 2005 | 759 | 0.100 |
Why?
| | rho-Associated Kinases | 3 | 2011 | 77 | 0.100 |
Why?
| | Nitroarginine | 5 | 2006 | 56 | 0.100 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 83 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 952 | 0.090 |
Why?
| | Premedication | 2 | 2024 | 45 | 0.090 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 77 | 0.090 |
Why?
| | Linear Models | 2 | 2025 | 857 | 0.090 |
Why?
| | Heart Septal Defects, Ventricular | 2 | 2026 | 44 | 0.090 |
Why?
| | Administration, Inhalation | 2 | 2007 | 567 | 0.090 |
Why?
| | Mothers | 1 | 2019 | 772 | 0.090 |
Why?
| | Isoenzymes | 2 | 2011 | 294 | 0.090 |
Why?
| | Vasodilator Agents | 2 | 2011 | 326 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 635 | 0.090 |
Why?
| | Apgar Score | 2 | 2023 | 20 | 0.080 |
Why?
| | Enzyme Inhibitors | 5 | 2009 | 823 | 0.080 |
Why?
| | Leadership | 1 | 2015 | 414 | 0.080 |
Why?
| | Sulfones | 3 | 2005 | 127 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1107 | 0.080 |
Why?
| | Pyridines | 4 | 2011 | 610 | 0.080 |
Why?
| | Infant, Low Birth Weight | 2 | 2022 | 154 | 0.080 |
Why?
| | Chronic Disease | 2 | 2014 | 1827 | 0.070 |
Why?
| | Prevalence | 3 | 2024 | 2861 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 271 | 0.070 |
Why?
| | Serotonin | 1 | 2011 | 297 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2025 | 11821 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3926 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2009 | 66 | 0.070 |
Why?
| | Amides | 2 | 2006 | 100 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 6077 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2009 | 449 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2002 | 1712 | 0.060 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.060 |
Why?
| | Estradiol | 2 | 2001 | 517 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 46 | 0.060 |
Why?
| | Cardiovascular Agents | 1 | 2008 | 165 | 0.060 |
Why?
| | Oxadiazoles | 3 | 2011 | 33 | 0.060 |
Why?
| | Comorbidity | 2 | 2024 | 1665 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3647 | 0.060 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2026 | 11 | 0.060 |
Why?
| | Hospitals, Low-Volume | 1 | 2026 | 26 | 0.060 |
Why?
| | Selenium | 1 | 2025 | 48 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2026 | 102 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 983 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2024 | 60 | 0.050 |
Why?
| | Chylothorax | 1 | 2024 | 20 | 0.050 |
Why?
| | Abnormalities, Multiple | 1 | 2026 | 195 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 140 | 0.050 |
Why?
| | Pyrazoles | 2 | 2005 | 517 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2024 | 164 | 0.050 |
Why?
| | Birth Weight | 1 | 2007 | 521 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 968 | 0.050 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 91 | 0.050 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 66 | 0.050 |
Why?
| | Hyperoxia | 1 | 2005 | 126 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 457 | 0.050 |
Why?
| | Parenteral Nutrition | 1 | 2024 | 102 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 219 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 43 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 525 | 0.050 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 85 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 109 | 0.050 |
Why?
| | Acetaminophen | 1 | 2025 | 268 | 0.040 |
Why?
| | Morpholines | 1 | 2002 | 130 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1064 | 0.040 |
Why?
| | Airway Extubation | 1 | 2022 | 60 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2001 | 790 | 0.040 |
Why?
| | Oligonucleotides | 1 | 2002 | 155 | 0.040 |
Why?
| | Gastroesophageal Reflux | 1 | 2024 | 232 | 0.040 |
Why?
| | Prostaglandins | 1 | 2001 | 94 | 0.040 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 37 | 0.040 |
Why?
| | Respiration | 1 | 2022 | 208 | 0.040 |
Why?
| | Artifacts | 1 | 2022 | 143 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2025 | 571 | 0.040 |
Why?
| | Piperazines | 3 | 2011 | 368 | 0.040 |
Why?
| | Image Enhancement | 1 | 2022 | 198 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 13 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 355 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2022 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 384 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 25 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4351 | 0.040 |
Why?
| | Epinephrine | 1 | 2020 | 160 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 158 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 65 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2000 | 140 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 84 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 4 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 8 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1468 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2020 | 62 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 421 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4595 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 225 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 106 | 0.040 |
Why?
| | Body Temperature | 1 | 2020 | 228 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 223 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2791 | 0.030 |
Why?
| | Contrast Media | 1 | 2022 | 493 | 0.030 |
Why?
| | Reference Values | 1 | 2000 | 796 | 0.030 |
Why?
| | Benchmarking | 1 | 2020 | 193 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 406 | 0.030 |
Why?
| | Blood Vessels | 1 | 2000 | 164 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 291 | 0.030 |
Why?
| | Surgical Mesh | 1 | 2018 | 54 | 0.030 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 188 | 0.030 |
Why?
| | Cesarean Section | 1 | 2000 | 230 | 0.030 |
Why?
| | Operating Rooms | 1 | 2020 | 145 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2022 | 582 | 0.030 |
Why?
| | Program Development | 1 | 2020 | 371 | 0.030 |
Why?
| | Sterilization | 1 | 2017 | 24 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 902 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 171 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 108 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1503 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 534 | 0.030 |
Why?
| | Acetylcholine | 2 | 2009 | 209 | 0.030 |
Why?
| | Risk Assessment | 2 | 2018 | 3712 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 999 | 0.030 |
Why?
| | Patient Care Team | 1 | 2021 | 701 | 0.030 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2005 | 17 | 0.030 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2005 | 23 | 0.030 |
Why?
| | Sildenafil Citrate | 2 | 2005 | 60 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 832 | 0.030 |
Why?
| | Burns | 1 | 2020 | 365 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 459 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 665 | 0.030 |
Why?
| | Purines | 2 | 2005 | 188 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4118 | 0.020 |
Why?
| | Vaccination | 1 | 2021 | 1449 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1221 | 0.020 |
Why?
| | Ketanserin | 1 | 2011 | 10 | 0.020 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 8 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 8 | 0.020 |
Why?
| | Sertraline | 1 | 2011 | 26 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 33 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 76 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 70 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 56 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 151 | 0.020 |
Why?
| | Kidney | 1 | 2018 | 1498 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 486 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 337 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8123 | 0.020 |
Why?
| | Constriction | 1 | 2008 | 45 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 511 | 0.020 |
Why?
| | Signal Transduction | 3 | 2006 | 5246 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 11913 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2008 | 507 | 0.010 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2004 | 53 | 0.010 |
Why?
| | Organ Size | 1 | 2005 | 465 | 0.010 |
Why?
| | Heart Atria | 1 | 2004 | 139 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 189 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 400 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 419 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 32 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 54 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 18 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.010 |
Why?
| | Aorta | 1 | 2004 | 440 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 82 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 64 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 80 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 166 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 307 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 678 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 163 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 405 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2537 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 497 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 152 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1177 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1463 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5586 | 0.010 |
Why?
|
|
Grover's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|